Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-11-20
1997-04-15
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31335
Patent
active
056210019
ABSTRACT:
Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
REFERENCES:
W.W. ten Bokkel Huinink, "Taxol, The First Available Of Taxanes, A New Class of Anticancer Drugs," vol. 3, Suppl. 1, pp. 244 (Nov. 3, 1992).
Longnecker et al., "Phase I and Pharmacokinetic Study of Taxol in Patients with Advanced Cancer,"Proceedings of the American Society of Clinical Oncology, vol. 4, p. 32 (Mar. 1985).
T. Thigpen et al., "Phase II Trial of Taxol as Second-Line Therapy for Ovarian Carcinoma: A Gynecologic Oncology Group Study," Proceedings of ASCO, vol. 9, p. 156 (Mar. 1990).
Sewa S. Legha, MD. et al., "A Phase II Trial of Taxol in Metastatic Melanoma," No. 11, pp. 2478-1481 (Nov. 8, 1989).
Eric K. Rowinsky et al., "Taxol: A Novel Investigational Antimicrotubule Agent," vol. 82, No. 15, pp. 1247-1259 (Aug. 1, 1990).
Avi I. Einzig et al., "A phase II study of taxol in patients with malignant melanoma," Investigational New Drugs 9, pp. 59-64 (1991).
Mcguire et al., "Taxol: A Unique Antineoplastic Agent with Significant Activity Against Advanced Ovarian Epithelial Neoplasms," Ann. Int. Med., 111, 273-279 (1989).
Brown et al., "A Phase I Trial of Taxol Given by a 6-Hour Intravenous Infusion," Journal of Clinical Oncology, vol. 9, No. 7, pp. 1261-1267 (Jul. 1991).
Kris et al., "Phase I Trial of Taxol Given as a 3-Hour Infusion Every 21 Days," Cancer Treatment Reports, vol. 70, No. 5, pp. 605-607, (May 1986).
Einzig et al., "Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma," Cancer Investigation, 9(2) 133-136 (1991).
A.B. Miller et al., "Reporting Results of Cancer Treatment," Cancer, vol. 47, pp. 207-214 (1981).
Koeller et al., "A Phase I/Pharmacokinetic Study of Taxol Given by a Prolonged Infusion Without Premedication," Proceedings of ASCO, vol. 8, p. 82 (Mar. 1989).
Wiernik et al., "Phase I Clinical and Pharmacokinetic Study of Taxol," Cancer Research, 47, 2486-2493 (May 1, 1987).
Legha et al., "Phase I Study of Taxol Using a 5-Day Intermittent Schedule," Journal of Clinical Oncology, vol. 4, No. 5, pp. 762-766 (May 1986).
Rowinsky et al., "Phase I Study of Taxol in Refractory Adult Acute Leukemia," Proceedings of AACR, vol. 29, p. 215 (Mar. 1985).
Gremm et al., "Phase I Study of Taxol Administered as a Short IV Infusion Daily for 5 Days," Cancer Treatment Reports, 71, 1179-1184 (1987).
Donehower et al., "Phase I Trial of Taxol in Patients with Advanced Cancer," Cancer Treatment Reports, vol. 71, No. 12 (Dec. 1987).
Holmes et al., "Phase II Study of Taxol in Patients (PT) with Metastatic Breast Cancer (MBC)," Proceedings of the American Society of Clinical Oncology, vol. 10, p. 60 (Mar. 1991).
Suffness, "Development of Antitumor Natural Products at the National Cancer Institute," Gann Monograph on Cancer Research, 36, pp. 21-44 (1989).
Weiss et al., "Hypersensitivity Reactions from Taxol," Journal of Clinical Oncology, vol. 8, No. 7, pp. 1263-1268 (Jul. 1990).
Sorosy et al., "Phase I Study of Taxol and Granulocyte Colony-Stimulating Factor in Patients with Refractory Ovarian Cancer," Journal of Clinical Oncology, vol. 10, No. 7, pp. 1165-1170 (Jul. 1992).
Ohnuma et al., "Phase I Study of Taxol in a 24-Hour Infusion Schedule," Proceedings of AACR, vol. 26, p. 167 (Mar. 1985).
Wiernik et al., "Phase I Trial of Taxol Given as a 24-Hour Infusion Every 21 Days: Response Observed in Metastatic Melanoma", Journal of Clinical Oncology, vol. 5, No. 8, pp. 1232-1239 (Aug. 1987).
Brown et al., "Taxol: Women with Ovarian Cancer Participate in a New Clinical Trial," Canadian Oncology Nursing Journal, 47-50 (Feb. 2, 1992).
Donehower et al., Cancer Treatment Reports, vol. 71, No. 12, Dec., 1987, pp. 1171-1177.
Canetta Renzo M.
Eisenhauer Elizabeth
Rozencweig Marcel
Bristol--Myers Squibb Company
Goldberg Jerome D.
LandOfFree
Methods for administration of taxol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for administration of taxol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for administration of taxol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-361146